208 related articles for article (PubMed ID: 37480158)
1. Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation.
Kitko CL; Bollard CM; Cairo MS; Chewning J; Fry TJ; Pulsipher MA; Shenoy S; Wall DA; Levine JE
Pediatr Blood Cancer; 2023 Sep; 70 Suppl 6(Suppl 6):e30577. PubMed ID: 37480158
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study.
Davies SM; Iannone R; Alonzo TA; Wang YC; Gerbing R; Soni S; Kolb EA; Meshinchi S; Orchard PJ; Burns LJ; Shenoy S; Leung W
Biol Blood Marrow Transplant; 2020 Apr; 26(4):712-717. PubMed ID: 31870931
[TBL] [Abstract][Full Text] [Related]
3. Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
Tsai SB; Rhodes J; Liu H; Shore T; Bishop M; Cushing MM; Gergis U; Godley L; Kline J; Larson RA; Mayer S; Odenike O; Stock W; Wickrema A; van Besien K; Artz AS
Biol Blood Marrow Transplant; 2018 May; 24(5):997-1004. PubMed ID: 29288821
[TBL] [Abstract][Full Text] [Related]
4. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.
Schetelig J; Baldauf H; Koster L; Kuxhausen M; Heidenreich F; de Wreede LC; Spellman S; van Gelder M; Bruno B; Onida F; Lange V; Massalski C; Potter V; Ljungman P; Schaap N; Hayden P; Lee SJ; Kröger N; Hsu K; Schmidt AH; Yakoub-Agha I; Robin M
Front Immunol; 2020; 11():584520. PubMed ID: 33542712
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
6. Donor Killer Immunoglobulin-Like Receptor Profile Bx1 Imparts a Negative Effect and Centromeric B-Specific Gene Motifs Render a Positive Effect on Standard-Risk Acute Myeloid Leukemia/Myelodysplastic Syndrome Patient Survival after Unrelated Donor Hematopoietic Stem Cell Transplantation.
Bao X; Wang M; Zhou H; Zhang H; Wu X; Yuan X; Li Y; Wu D; He J
Biol Blood Marrow Transplant; 2016 Feb; 22(2):232-239. PubMed ID: 26371372
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil.
Tavares RCB; Bonfim CS; Seber A; Pereira Lermontov S; Coulturato V; Zecchin VG; Ribeiro L; Fernandes JF; Daudt LE; Grecco CS; Darrigo-Jr LG; Villela N; Nichele S; Gouveia R; Bouzas LF; Hamerschlak N; Vigorito AC; da Silva PM; da Silva PO; da Silva CC; de Souza Fernandez C; Flowers ME; Arcuri LJ
Pediatr Transplant; 2020 Nov; 24(7):e13789. PubMed ID: 32757316
[TBL] [Abstract][Full Text] [Related]
8. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
9. Peritransplantation Glucocorticoid Haploidentical Stem Cell Transplantation Is a Promising Strategy for AML Patients With High Leukemic Burden: Comparison With Transplantations Using Other Donor Types.
Kaida K; Ikegame K; Inoue T; Maruyama S; Ishii S; Uchida N; Doki N; Eto T; Fukuda T; Katayama Y; Takada S; Kawakita T; Ichinohe T; Atsuta Y; Daimon T; Ogawa H
Transplant Cell Ther; 2023 Apr; 29(4):273.e1-273.e9. PubMed ID: 36641032
[TBL] [Abstract][Full Text] [Related]
10. External validation of models for KIR2DS1/KIR3DL1-informed selection of hematopoietic cell donors fails.
Schetelig J; Baldauf H; Heidenreich F; Massalski C; Frank S; Sauter J; Stelljes M; Ayuk FA; Bethge WA; Bug G; Klein S; Wendler S; Lange V; de Wreede LC; Fürst D; Kobbe G; Ottinger HD; Beelen DW; Mytilineos J; Fleischhauer K; Schmidt AH; Bornhäuser M
Blood; 2020 Apr; 135(16):1386-1395. PubMed ID: 31932846
[TBL] [Abstract][Full Text] [Related]
11. Busulfan, fludarabine, and melphalan are effective conditioning for pediatric and young adult patients with myeloid malignancies underdoing matched sibling or alternative donor transplantation.
Truscott L; Pariury H; Hanmod S; Davini M; de la Maza M; Sapp LN; Staples K; Proytcheva M; Katsanis E
Pediatr Blood Cancer; 2023 Feb; 70(2):e30102. PubMed ID: 36394072
[TBL] [Abstract][Full Text] [Related]
12. The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia.
Keating AK; Langenhorst J; Wagner JE; Page KM; Veys P; Wynn RF; Stefanski H; Elfeky R; Giller R; Mitchell R; Milano F; O'Brien TA; Dahlberg A; Delaney C; Kurtzberg J; Verneris MR; Boelens JJ
Blood Adv; 2019 Apr; 3(7):1118-1128. PubMed ID: 30952678
[TBL] [Abstract][Full Text] [Related]
13. A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Spitzer B; Jakubowski AA; Papadopoulos EB; Fuller K; Hilden PD; Young JW; Barker JN; Koehne G; Perales MA; Hsu KC; van den Brink MR; Kernan NA; Prockop SE; Scaradavou A; Castro-Malaspina H; O'Reilly RJ; Boulad F
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2088-2095. PubMed ID: 28711727
[TBL] [Abstract][Full Text] [Related]
14. Effect of graft source on unrelated donor hemopoietic stem cell transplantation in adults with acute myeloid leukemia after reduced-intensity or nonmyeloablative conditioning: a study from the Société Francaise de Greffe de Moelle et de Thérapie Cellulaire.
Malard F; Milpied N; Blaise D; Chevallier P; Michallet M; Lioure B; Clément L; Hicheri Y; Cordonnier C; Huynh A; Yakoub-Agha I; Peffault de Latour R; Mohty M
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1059-67. PubMed ID: 25708220
[TBL] [Abstract][Full Text] [Related]
15. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
17. Comparable survival for pediatric acute myeloid leukemia with poor-risk cytogenetics following chemotherapy, matched related donor, or unrelated donor transplantation.
Kelly MJ; Horan JT; Alonzo TA; Eapen M; Gerbing RB; He W; Lange BJ; Parsons SK; Woods WG
Pediatr Blood Cancer; 2014 Feb; 61(2):269-75. PubMed ID: 23955900
[TBL] [Abstract][Full Text] [Related]
18. Poor outcome with nonmyeloablative conditioning regimen before cord blood transplantation for patients with high-risk acute myeloid leukemia compared with matched related or unrelated donor transplantation.
Devillier R; Harbi S; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Etienne A; Calmels B; Lemarie C; Prebet T; Granata A; Charbonnier A; Rey J; Chabannon C; Faucher C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1560-5. PubMed ID: 24933658
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia.
Zheng C; Zhu X; Tang B; Yao W; Song K; Tong J; Geng L; Liu H; Sun Z
Ann Hematol; 2015 Mar; 94(3):473-80. PubMed ID: 25217231
[TBL] [Abstract][Full Text] [Related]
20. Unrelated or haploidentical allogeneic hematopoietic cell transplantation in second complete remission for acute myeloid leukemia-Improved outcomes over time: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party study.
Al Hamed R; Ngoya M; Galimard JE; Sengeloev H; Gedde-Dahl T; Kulagin A; Platzbecker U; Yakoub-Agha I; Byrne JL; Valerius T; Socie G; Kröger N; Blaise D; Bazarbachi A; Sanz J; Ciceri F; Nagler A; Mohty M
Cancer; 2023 Sep; 129(17):2645-2654. PubMed ID: 37269074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
